About cingulate inc - CING
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.
CING At a Glance
Cingulate, Inc.
1901 West 47th Place
Kansas City, Kansas 66205
| Phone | 1-913-942-2300 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -22,449,911.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CING Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 12.542 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.019 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.444 |
CING Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,603,565.071 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CING Liquidity
| Current Ratio | 1.159 |
| Quick Ratio | 1.159 |
| Cash Ratio | 1.062 |
CING Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -149.977 |
| Return on Equity | -450.602 |
| Return on Total Capital | -198.752 |
| Return on Invested Capital | -306.42 |
CING Capital Structure
| Total Debt to Total Equity | 350.214 |
| Total Debt to Total Capital | 77.788 |
| Total Debt to Total Assets | 58.292 |
| Long-Term Debt to Equity | 89.749 |
| Long-Term Debt to Total Capital | 19.935 |